Cesare Cozzarini1, Tiziana Rancati2, Viviana Carillo3, Francesco Civardi4, Elisabetta Garibaldi5, Pierfrancesco Franco6, Barbara Avuzzi7, Claudio Degli Esposti8, Giuseppe Girelli9, Cinzia Iotti10, Federica Palorini3, Vittorio Vavassori11, Riccardo Valdagni12, Claudio Fiorino3. 1. Radiotherapy, San Raffaele Scientific Institute, Milano, Italy. 2. Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: tiziana.rancati@istitutotumori.mi.it. 3. Medical Physics, San Raffaele Scientific Institute, Milano, Italy. 4. Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 5. Radiotherapy, IRCCS-Candiolo, Italy. 6. Radiotherapy, Ospedale Regionale U.Parini-AUSL Valle d'Aosta, Italy. 7. Radiation Oncology 1,Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. 8. Radiotherapy, Ospedale Bellaria, Bologna, Italy. 9. Radiotherapy, Ospedale ASL9, Ivrea, Italy. 10. Radiation Therapy Unit, Department of Oncology and Advanced Technology, ASMN Hospital IRCCS, Reggio Emilia, Italy. 11. Radiotherapy, Cliniche Gavazzeni-Humanitas, Bergamo, Italy. 12. Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Radiation Oncology 1,Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Abstract
PURPOSE: A prospective trial started in 2010, aiming at developing models for urinary toxicity and erectile dysfunction after radiotherapy for prostate cancer. This analysis is finalised at highlighting correlations between clinical/dosimetric factors and acute urinary specific symptoms, as measured by single questions of the International Prostate Symptom Score (IPSS). MATERIALS/ METHODS: IPSS was prospectively collected before and at the end of radiotherapy; absolute weekly bladder dose-surface histograms (DSHw) were chosen as dosimetric descriptors. Relevant clinical factors were prospectively gathered. Backward feature selection was used to identify variables to be included in logistic models for moderate-severe (scores⩾4) urinary symptoms. RESULTS: Complete data of 262 patients (120 conventional fractionation, 142 hypofractionation) were available. Smoking was a strong predictor for feeling of incomplete emptying, frequency, intermittency, urgency and straining; neoadjuvant hormonal therapy and use of antihypertensive drugs were risk factors for intermittency and weak stream, respectively. The baseline score was a major predictor for all symptoms with the exception of intermittency. DSHw were correlated to increased risk of frequency, intermittency, urgency and nocturia. Most models showed moderate-high discrimination (AUC≈0.60-0.79). CONCLUSIONS: Smoking and other clinical and dosimetric factors predict for specific moderate-severe acute urinary symptoms; baseline condition heavily modulated the risk in most endpoints.
PURPOSE: A prospective trial started in 2010, aiming at developing models for urinary toxicity and erectile dysfunction after radiotherapy for prostate cancer. This analysis is finalised at highlighting correlations between clinical/dosimetric factors and acute urinary specific symptoms, as measured by single questions of the International Prostate Symptom Score (IPSS). MATERIALS/ METHODS: IPSS was prospectively collected before and at the end of radiotherapy; absolute weekly bladder dose-surface histograms (DSHw) were chosen as dosimetric descriptors. Relevant clinical factors were prospectively gathered. Backward feature selection was used to identify variables to be included in logistic models for moderate-severe (scores⩾4) urinary symptoms. RESULTS: Complete data of 262 patients (120 conventional fractionation, 142 hypofractionation) were available. Smoking was a strong predictor for feeling of incomplete emptying, frequency, intermittency, urgency and straining; neoadjuvant hormonal therapy and use of antihypertensive drugs were risk factors for intermittency and weak stream, respectively. The baseline score was a major predictor for all symptoms with the exception of intermittency. DSHw were correlated to increased risk of frequency, intermittency, urgency and nocturia. Most models showed moderate-high discrimination (AUC≈0.60-0.79). CONCLUSIONS: Smoking and other clinical and dosimetric factors predict for specific moderate-severe acute urinary symptoms; baseline condition heavily modulated the risk in most endpoints.
Authors: Michael C Repka; Shan Guleria; Robyn A Cyr; Thomas M Yung; Harsha Koneru; Leonard N Chen; Siyuan Lei; Brian T Collins; Pranay Krishnan; Simeng Suy; Anatoly Dritschilo; John Lynch; Sean P Collins Journal: Front Oncol Date: 2016-05-18 Impact factor: 6.244
Authors: Rowan V David; Arman A Kahokehr; Jason Lee; David I Watson; John Leung; Michael E O'Callaghan Journal: World J Urol Date: 2022-08-11 Impact factor: 3.661
Authors: Panayiotis Mavroidis; Kevin A Pearlstein; John Dooley; Jasmine Sun; Srinivas Saripalli; Shiva K Das; Andrew Z Wang; Ronald C Chen Journal: Radiat Oncol Date: 2018-02-02 Impact factor: 3.481
Authors: Stefania Zuppone; Andrea Bresolin; Antonello E Spinelli; Giuseppe Fallara; Roberta Lucianò; Federico Scarfò; Fabio Benigni; Nadia Di Muzio; Claudio Fiorino; Alberto Briganti; Andrea Salonia; Francesco Montorsi; Riccardo Vago; Cesare Cozzarini Journal: Front Oncol Date: 2020-10-22 Impact factor: 6.244